Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Transarterial Chemoembolization (TACE) Plus Hepatic Arterial Infusion Chemotherapy (HAIC) With Oxaliplatin and Raltitrexed for Barcelona Stage C Hepatocellular Carcinoma (HCC)

NCT04597970 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT04597970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Transarterial Chemoembolization (TACE) Plus Hepatic Arterial Infusion Chemotherapy (HAIC) With Oxaliplatin and Raltitrexed for Barcelona Stage C Hepatocellular Carcinoma (HCC)
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Unknown status
Start date
October 20, 2020
Completion date
October 20, 2022
Enrollment
66 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, transarterial chemoembolization